Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 5:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Healthy Adults
Interventions: Vaccine Candidate #1, Vaccine Candidate #2, Vaccine Candidate #3, Vaccine Candidate #4, Vaccine Candidate #5, Vaccine Candidate #6, TIV1 or TIV2; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 770 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 15
States / cities: Mobile, Alabama • Walnut Creek, California • Milford, Connecticut + 12 more

Conditions: Influenza
Interventions: VIS410, Placebo; Drug
Lead sponsor: Visterra, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Influenza, Myxovirus Infection
Interventions: Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1), Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2), Split, Inactivated, Trivalent Influenza Vaccine (Standard dose), Split, Inactivated, Trivalent Influenza Vaccine (High-dose); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 2,098 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 29
States / cities: Alabaster, Alabama • Mobile, Alabama • Chandler, Arizona + 26 more

Conditions: HIV-1 Infection, H1N1, Influenza, Flu
Interventions: FluMist, Fluvirin, Fluzone; Biological
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 6 Months to 25 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more

Conditions: Influenza
Interventions: FLUGEN 101.2 device; Device
Lead sponsor: FluGen Inc; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Melbourne, Florida

Conditions: Influenza
Interventions: Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza Viral Infections
Interventions: Sofia Influenza A+B FIA; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 0 Years and older
Enrollment: 1,181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Fever After Vaccination, Fever, Febrile Seizure
Interventions: PCV13, DTaP, IIV; Biological
Lead sponsor: Duke University; Other
Eligibility: 12 Months to 16 Months
Enrollment: 221 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Oakland, California • Atlanta, Georgia • Durham, North Carolina

Conditions: Influenza, Swine-origin A/H1N1 Influenza
Interventions: Monovalent Subvirion A/H1N1 Influenza vaccine, Normal saline solution (placebo); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 9 Years
Enrollment: 474 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 20
States / cities: Miami Beach, Florida • Marietta, Georgia • Woodstock, Georgia + 16 more

Conditions: Aging, Influenza Vaccine, Dendritic Cell, Vaccine Response
Interventions: Flu Vaccine (Year 1), Flu Vaccine (Year 2), Flu Vaccine (Year 3), Flu Vaccine (Year 4); Biological
Lead sponsor: The Jackson Laboratory; Other
Eligibility: 65 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Influenza, Human
Interventions: 3.75 ug Panblok H7, 7.5 ug Panblok H7, 15 ug Panblok H7, MF59, AS03; Biological
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 366 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Lenexa, Kansas • Wichita, Kansas • Lexington, Kentucky + 1 more

Conditions: Influenza, Influenza Immunisation
Interventions: Influenza Multimeric-001 Vaccine, Placebo, Quadrivalent Recombinant Seasonal Influenza Vaccine; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Iowa City, Iowa • Cincinnati, Ohio • Houston, Texas

Conditions: Healthy Participants
Interventions: Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF, QIV, Normal Saline Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 1,142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 37
States / cities: Dublin, California • Huntington Beach, California • Lake Forest, California + 26 more

Conditions: Influenza
Interventions: CAIV-T; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000
U.S. locations: 1
States / cities: Stamford, Connecticut

Conditions: Influenza
Interventions: Reminder; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 139,503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions: trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis; Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 459 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: Influenza A
Interventions: Pimodivir 600 mg, Placebo, SOC Treatment; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 13 Years to 85 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 28
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Fresno, California + 23 more

Conditions: Influenza Vaccination
Interventions: Opting Out; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Galveston, Texas • Houston, Texas

Conditions: Rheumatoid Arthritis
Interventions: CP-690,550, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 51
States / cities: Gilbert, Arizona • Paradise Valley, Arizona • Jonesboro, Arkansas + 45 more

Conditions: Influenza, Human
Interventions: bioCSL Trivalent Influenza Virus Vaccine (CSL TIV), Comparator Quadrivalent Influenza Virus Vaccine; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 5 Years to 8 Years
Enrollment: 402 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 11
States / cities: Los Angeles, California • Boise, Idaho • St Louis, Missouri + 8 more

Conditions: Influenza, Respiratory Tract Infections
Interventions: Portal Reminders for Influenza Vaccination: Direct scheduling link, Portal Reminders for Influenza Vaccination: No direct scheduling link, Pre-Commitment Prompt, Pre-Appointment flu vaccine reminders; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 4 Months and older
Enrollment: 213,773 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Influenza
Interventions: Fluzone, Fluad; Biological
Lead sponsor: Yale University; Other
Eligibility: 21 Years and older
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pneumococcal Disease
Interventions: 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 1,390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more

Conditions: Influenza
Interventions: Inactivated Influenza A Vaccine A/H5N1, Placebo (IM), Placebo (ID); Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 227 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

A Study to Learn About mRNA Vaccines Against Influenza in Adults

A Study of VIS410 to Assess Safety and Pharmacokinetics

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth

Intracutaneous Delivery of Varied Dose Volumes of Saline

H9 Priming Study in Healthy Adults

Nasal Swab Home Collection Kit (NSHC Kit) Study

Fever After Simultaneous Versus Sequential Vaccination in Young Children

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years

A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults

Panblok H7 Vaccine Adjuvanted With AS03 or MF59

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults

Nudging Flu Vaccination by Making it Easy for Patients to Schedule a Flu Shot

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

Opting In vs Opting Out

A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo

A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- UCLA Portal R/R Influenza RCT 3

Systems Investigation of Vaccine Responses in Aging and Frailty

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

Higher Dose Intradermal H5 Vaccine